ALLAKOS INC. - COMMON STOCK

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

06 مارس 2023 16:02:00 بحسب Nasdaq GlobeNewswire

Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology

29 نوفمبر 2022 07:02:00 بحسب Nasdaq GlobeNewswire

Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting

10 نوفمبر 2022 09:02:00 بحسب Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results

07 نوفمبر 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock

19 سبتمبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)

12 سبتمبر 2022 07:02:00 بحسب Nasdaq GlobeNewswire

Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis

09 سبتمبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results

04 أغسطس 2022 16:04:00 بحسب Nasdaq GlobeNewswire

Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors

25 يوليو 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports First Quarter 2022 Financial Results

06 مايو 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

01 مارس 2022 16:05:01 بحسب Nasdaq GlobeNewswire

Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases

21 ديسمبر 2021 19:14:59 بحسب Nasdaq GlobeNewswire

Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma

30 نوفمبر 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results

08 نوفمبر 2021 16:05:01 بحسب Nasdaq GlobeNewswire

Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic Evaluation

25 أكتوبر 2021 08:00:01 بحسب Nasdaq GlobeNewswire

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting

24 أكتوبر 2021 15:35:00 بحسب Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results

09 أغسطس 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)

07 يونيو 2021 08:00:00 بحسب Nasdaq GlobeNewswire

New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms

24 مايو 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Allakos Reports First Quarter 2021 Financial Results and Provides Business Update

10 مايو 2021 16:01:00 بحسب Nasdaq GlobeNewswire